TCR2 Therapeutics, a early stage biotech developing immunotherapies for various cancers, raised $75 million by offering 5 million shares at $15, the midpoint of the $14 to $16 range. TCR2 Therapeutics plans to list on the Nasdaq under the symbol TCRR. Jefferies, SVB Leerink and BMO Capital Markets acted as lead managers on the deal.
